Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting by Rosencher, Nadia et al.
Rosencher et al. Thrombosis Journal  (2016) 14:8 
DOI 10.1186/s12959-016-0082-4ORIGINAL CLINICAL INVESTIGATION Open AccessDabigatran etexilate for thromboprophylaxis
in over 5000 hip or knee replacement patients
in a real-world clinical setting
Nadia Rosencher1*, Charles M. Samama1, Martin Feuring2,3, Martina Brueckmann2,3, Eva Kleine3,
Andreas Clemens3 and Simon Frostick4Abstract
Background: Thromboprophylaxis is recommended for patients undergoing total hip or total knee replacement
(THR, TKR). An international, open-label, prospective, observational, single-arm study in a routine clinical setting was
performed to assess the safety and efficacy of dabigatran etexilate 220 mg once daily in patients undergoing THR
or TKR, and in subgroups of patients with potentially increased risk of bleeding or venous thromboembolism (VTE).
Materials and methods: Patients were ≥18 years and required to be eligible to receive dabigatran 220 mg once
daily (first dose 110 mg 1–4 h after THR/TKR surgery) according to the European Summary of Product Characteristics.
The primary safety and efficacy outcomes were incidence of major bleeding events (MBEs), and the composite
incidence of symptomatic VTE events and all-cause mortality, respectively.
Results: In total, 5292 patients (median age 64 years) were enrolled and received dabigatran (2734 THR and 2558 TKR).
Median drug exposure was 31 days (THR 34 days; TKR 27 days). Overall incidence of MBEs was 0.72 % (95 % confidence
interval [CI] 0.51, 0.98), and this rate was comparable between types of surgery and was not significantly affected by
protocol-defined risk factors. The overall incidence of symptomatic VTE and all-cause mortality was 1.04 % (95 % CI
0.78, 1.35); the only significant risk factor was history of VTE events (odds ratio 5.59; 95 % CI 2.53, 11.08). A post-hoc
analysis showed that the incidence of MBEs in this observational study was similar to or lower than those reported in
previous phase 3 trials.
Conclusions: Results from this observational study of dabigatran etexilate administered to patients undergoing THR or
TKR surgery are reassuring and supportive of those obtained in dabigatran phase 3 trials.
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Keywords: Dabigatran etexilate, Observational study, Thromboprophylaxis, Total hip replacement, Total knee
replacement* Correspondence: nadia.rosencher@cch.aphp.fr
1Department of Anaesthesia and Intensive Care Medicine, Cochin University
Hospital, Assistance-Publique – Hôpitaux de Paris; Université Paris Descartes,
Paris, France
Full list of author information is available at the end of the article
© 2016 Rosencher et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rosencher et al. Thrombosis Journal  (2016) 14:8 Page 2 of 10Background
Patients undergoing total hip or total knee replacement
(THR, TKR) are at risk of developing venous
thromboembolic events and therefore, thrombopro-
phylaxis is recommended [1]. Compared with low-
molecular-weight heparin (LMWH) administered
subcutaneously, oral anticoagulants such as dabiga-
tran etexilate (hereafter described as dabigatran)
offer important practical advantages. Dabigatran, a
low-molecular-weight, reversible thrombin inhibitor,
is recommended for primary prevention of venous
thromboembolism (VTE) in THR and TKR [1] and
has been approved for this indication in more than
100 countries.
Dabigatran is 80 % renally excreted and its terminal
half-life is approximately 11–17 h [2, 3]. The European
Medicines Agency recommends dabigatran at a dose of
220 mg once daily for the primary prevention of VTE in
patients undergoing orthopaedic surgery [3]. For patients
with moderate renal impairment, and for those aged
≥75 years or receiving concomitant amiodarone or
quinidine, a reduced dose of 150 mg once daily is rec-
ommended [3]. Both doses of dabigatran should be initi-
ated 1–4 h after surgery with a half dose to mitigate the
bleeding risk in the vulnerable post-operative phase.
The efficacy and safety of dabigatran in the primary pre-
vention of VTE after elective THR or TKR was demon-
strated in the phase 3 studies, RE-MODEL [4], RE-
MOBILIZE [5], RE-NOVATE [6] and RE-NOVATE II [7].
More than 10,000 patients were randomised in these trials
and approximately 6400 received dabigatran. The pooled
analysis of the RE-MODEL, RE-MOBILIZE and RE-
NOVATE trials showed that dabigatran had similar effi-
cacy to enoxaparin in the prevention of major VTE and
VTE-related mortality after knee or hip replacement [8].
The results of the RE-NOVATE II trial were consistent
with these findings [7]. No statistically significant dif-
ferences in the incidence of major bleeding events
(MBEs) between treatment groups were found, and
no safety concerns regarding elevations in liver func-
tion tests or acute coronary syndrome (ACS) events
were identified [4, 6–9].
This report provides the results from a large, real-world,
observational study of dabigatran in patients undergoing
THR or TKR in a routine clinical setting. The purpose of
this study was to assess the safety and efficacy of dabiga-
tran 220 mg once daily in all patients who received the
drug, as well as in protocol-defined subgroups of patients
who had a potentially increased risk of bleeding and/
or VTE (i.e. patients with special comorbidities or
comedication). This is the first study to provide an
insight into the outcomes following use of dabiga-
tran for the prevention of VTE in a real-world
orthopaedic setting.Methods
Study design and setting
This was an international, open-label, prospective, ob-
servational, single-arm study of patients undergoing
elective THR or TKR surgery (clinical trial.gov identifier:
NCT00846807). Patients were recruited from 110 sites in
nine countries in the European Union. The study was
approved by the local institutional ethics committees on
human research in the participating centres (Additional
file 1: Independent Ethics Committees/Institutional Review
Board). All participants provided informed consent.
Participants and visits
Patients were to be ≥18 years old, undergoing elective THR
or TKR and eligible for dabigatran (PRADAXA®, Boehrin-
ger Ingelheim, Ingelheim, Germany) 220 mg once daily
(first dose 110 mg 1–4 h after surgery) according to the
European Summary of Product Characteristics [3] (further
details in Additional file 1: Supplementary Methods). Risk
factors for VTE events were recorded and patients were
assigned to protocol-defined subgroups of interest. These
were as follows: active smoking (including patients who
interrupted smoking in the peri-operative period [±10 days]);
history of coronary artery disease (CAD) or chronic heart
failure (CHF; New York Heart Association classification
II–IV) ≤6 months before surgery; patients with a history of
VTE who were not on any anticoagulant treatment at the
time of inclusion in the study; concomitant acetylsalicylic
acid (ASA) medication; and patients with chronic use of
non-steroidal anti-inflammatory drugs (NSAIDs).
The three assessment visits were a baseline visit ≤7 days
before surgery; a second visit, either at discharge from hos-
pital or 24–48 h after the last dose of dabigatran (which-
ever was the earliest); and a follow-up visit if hospital
discharge occurred before the end of treatment (24–48 h
after the last dose of dabigatran treatment, e.g. by tele-
phone). All patients provided written informed consent.
Outcomes
The primary safety endpoint was the incidence of MBEs
[10]. These were defined as: clinically overt bleeding asso-
ciated with a ≥20 g/L fall in haemoglobin in excess of that
expected or leading to transfusion of ≥2 units of packed
cells/whole blood in excess of that expected; fatal, retro-
peritoneal, intracranial, intraocular or intraspinal bleeding;
or bleeding warranting treatment cessation or leading to
re-operation and including wound site (consistent with
the Control of Anticoagulation Subcommittee of the
International Society on Thrombosis and Haemostasis
definition) [10]. Bleeding events that did not meet the cri-
teria for MBE were recorded as any bleeding event.
The primary efficacy variable was the composite of
symptomatic VTE (sVTE) (defined as the symptomatic
proximal and distal deep vein thrombosis [DVT] and
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on the investigator’s clinical judgement) and all-cause
mortality. All VTEs were confirmed via ultrasound, ven-
ography or Doppler echocardiography. Nonfatal PEs
were all confirmed via pulmonary angiography or venti-
lation/perfusion (V/Q) scintigraphy.Fig. 1 Patient disposition flow diagram. Treated set included 64
noneligible patients. Eligibility to participate and reasons for
discontinuation were noted by investigators by completion of
tick boxes. SmPC Summary of Product CharacteristicsStatistical methods
Study size
The determination of sample size was based on the antici-
pated incidence of MBEs and sVTE, which were estimated
to be in the range of 0.5 to 2.0 % of the trial population.
Based on a sample of 5000 patients, the upper two-sided
95 % confidence limit for the rate estimate would be be-
tween 0.74 and 2.43 %. In addition, it was expected that a
sample size of 5000 (2500 in each surgery group) would
provide at least 400 patients within each of the protocol-
defined subgroups. It was estimated that this number of
patients would provide 80 % power to detect a rate differ-
ence for sVTE and MBE in subgroups of patients with and
without protocol-defined risk factors.Analysis
Data were summarised for the entire population by type
of surgery and by protocol-defined subgroups. All ana-
lyses were descriptive, including p values and confidence
intervals (CIs) (Clopper-Pearson [11]) and were used for
exploratory purposes only. Analyses of study endpoints
and adverse events (AEs) focused on the treatment period
(i.e. from first dose of dabigatran to 24 h after last dose).
Stratified analysis by surgery type was used to assess the
confounding of risk factors with surgery type. The associ-
ation between the presence of protocol-defined risk factors
for increased bleeding or VTE and the occurrence of out-
come events was assessed using univariable logistic regres-
sion analyses, and robustness of the results was checked
by running multivariable analyses adjusting for potential
confounders (e.g. age). Corresponding CIs and p values re-
ported were based on likelihood ratio statistics.Results
Patient disposition
This study was conducted from March 2009 to July
2011. In total, 5438 patients were enrolled and 5292 pa-
tients were treated (Fig. 1); 88.1 % of treated patients
completed dabigatran treatment and the rate of com-
pletion was similar for both THR and TKR. The most
frequent reason for premature discontinuation was an
AE (5.1 %; Fig. 1); the most common AEs leading to
discontinuation were events other than bleeding
events (3.8 %).Baseline characteristics and presence of protocol-defined
risk factors
The 5292 treated patients (2734 THR; 2558 TKR) were
included in all analyses. Baseline characteristics are
shown in Table 1; median drug exposure was 31 days
(THR 34 days; TKR 27 days). Of the 5292 patients,
38.2 % had ≥1 protocol-defined risk factor for increased
bleeding and/or VTE.
Mean creatinine clearance (CrCl) was 108.1 mL/min
(Table 1). The large standard deviation was primarily
driven by extremely high CrCl values. Only 1.1 % of pa-
tients had moderate renal impairment (due to exclusion
criteria for the study). On average, patients undergoing
TKR were older than those undergoing THR (mean age
was 65 vs 61 years) and had slightly higher body mass
index (BMI) (Table 1). In the THR group there were
fewer patients with any medical history compared with
the TKR group (p < 0.0001); this was reflected by fewer
patients with a history of hypertension, diabetes mellitus,
renal disease, myocardial infarction and gastrointestinal
bleeding. The most commonly used cardiovascular med-
ications were agents acting on the renin–angiotensin
system (20.6 %). In total, 3378 (63.8 %) patients used ≥1
concomitant nondrug therapy (elastic compression
stockings [52.9 %], other therapies [12.5 %] or surgical
therapies and interventions [2.0 %]). The use of such
therapies was similar for the two surgery groups.
The most common of the protocol-defined factors
were chronic use of NSAIDs, active smoking, concomi-
tant ASA use and CAD. Concomitant users of ASA were
fewer in the THR group than in the TKR group but the
Table 1 Baseline patient characteristics – treated set
THR TKR P valuea Total
Treated, n 2734 2558 5292
Male, n (%) 1293 (47.3) 938 (36.7) <0.0001 2231 (42.2)
Age (years), mean (SD) 60.8 (10.22) 64.6 (7.50) <0.0001 62.6 (9.20)
Age by category <0.0001
<65 years, n (%) 1586 (58.0) 1117 (43.7) 2703 (51.1)
≥65 years, n (%) 1148 (42.0) 1441 (56.3) 2589 (48.9)
BMI (kg/m2), mean (SD) 27.8 (4.74) 30.5 (5.25) <0.0001 29.1 (5.16)
CrCl [mL/min] at visit 1, mean (SD) 109.9 (115.73) 106.1 (70.71) 0.1425 108.1 (96.57)
Medical history
Any, n (%) 1357 (49.6) 1639 (64.1) <0.0001 2996 (56.6)
Hypertension, n (%) 1153 (42.2) 1448 (56.6) <0.0001 2601 (49.1)
Diabetes mellitus, n (%) 207 (7.6) 324 (12.7) <0.0001 531 (10.0)
Cancer, n (%) 179 (6.5) 197 (7.7) 0.1024 376 (7.1)
Liver disease, n (%) 59 (2.2) 64 (2.5) 0.4066 123 (2.3)
Renal disease, n (%) 44 (1.6) 73 (2.9) 0.0021 117 (2.2)
TIA/stroke, n (%) 44 (1.6) 54 (2.1) 0.1761 98 (1.9)
MI, n (%) 33 (1.2) 58 (2.3) 0.0030 91 (1.7)
GI bleeding, n (%) 23 (0.8) 42 (1.6) 0.0082 65 (1.2)
Immobilisation within the last 10 days 6 (0.2) 5 (0.2) 0.8481 11 (0.2)
Risk factor subgroups
Active smoker, n (%) 465 (17.0) 239 (9.3) <0.0001 704 (13.3)
CAD, n (%) 132 (4.8) 187 (7.3) 0.0001 319 (6.0)
CHF, n (%) 54 (2.0) 73 (2.9) 0.0369 127 (2.4)
History of VTE, n (%) 73 (2.7) 113 (4.4) 0.0006 186 (3.5)
Concomitant ASA, n (%) 166 (6.1) 252 (9.9) <0.0001 418 (7.9)
Chronic use of NSAIDs, n (%) 415 (15.2) 394 (15.4) 0.8214 809 (15.3)
aIn case of continuous variables t-test is applied; for categorical variables chi-square test is applied
ASA acetylsalicylic acid, BMI body mass index, CAD coronary artery disease, CHF chronic heart failure, CrCl creatinine clearance, GI gastrointestinal, MI myocardial
infarction, NSAIDs non-steroidal anti-inflammatory drugs, SD standard deviation, THR total hip replacement, TIA transient ischaemic attack, TKR total knee replacement,
VTE venous thromboembolism
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(Table 1). In the THR group, there were also significantly
fewer patients with a history of CAD, CHF and VTE
compared with the TKR group.Safety outcomes
The overall incidence of MBEs was 0.72 % (95 % CI
0.51, 0.98) (Table 2 and Additional file 1: Supplementary
Table 1). Protocol-defined risk factors (Table 2, Fig. 2)
and type of surgery (Table 2) had no significant effect on
the occurrence of MBEs. When comparing patients with
at least one risk factor with patients with none of the
risk factors, there was a comparable incidence of MBEs
(0.64 % and 0.76 %, respectively). Sensitivity analyses, in-
cluding several covariates in the logistic regression
model, support these results (results not shown).In patients who had MBEs (n = 38), the onset of the
events occurred during the first 7 days of treatment in
63.2 % (12/19) of patients in the THR group and 73.7 %
(14/19) in the TKR group. Onset occurred between 8 and
14 days after treatment initiation in 15.8 % (3/19) and
26.3 % (5/19) in the THR and TKR groups, respectively,
and >14 days after treatment initiation in 21.1 % (4/19) in
the THR group and none of the TKR group. Figure 3
shows the cumulative incidence of MBEs over time.
The overall incidence of any bleeding events was 3.82 %
(95 % CI 3.32, 4.37), with a slightly higher incidence for
knee surgery (4.61 %) compared with hip surgery (3.07 %)
patients. There were no fatal bleeds in the study.
Efficacy outcomes
The overall incidence of symptomatic VTE and all-cause
mortality was 1.04 % (95 % CI 0.78, 1.35). With the
Table 2 Incidence of MBEs overall and in protocol-defined risk factor subgroups – treated set
THR TKR Total
Risk factor subgroups N n Incidence % 95 % CI N n Incidence % 95 % CI N n Incidence % 95 % CI
All treated 2734 19 0.69 0.42, 1.08 2558 19 0.74 0.45, 1.16 5292 38 0.72 0.51, 0.98
Active smoker
No 2269 16 0.71 0.40, 1.14 2319 19 0.82 0.49, 1.28 4588 35 0.76 0.53, 1.06
Yes 465 3 0.65 0.13, 1.87 239 0 0 0.00, 1.53 704 3 0.43 0.09, 1.24
CAD
No 2602 18 0.69 0.41, 1.09 2371 18 0.76 0.45, 1.20 4973 36 0.72 0.51, 1.00
Yes 132 1 0.76 0.02, 4.15 187 1 0.53 0.01, 2.94 319 2 0.63 0.08, 2.25
CHF
No 2680 19 0.71 0.43, 1.10 2485 17 0.68 0.40, 1.09 5165 36 0.70 0.49, 0.96
Yes 54 0 0 0.00, 6.60 73 2 2.74 0.33, 9.55 127 2 1.57 0.19, 5.57
History of VTE
No 2661 19 0.71 0.43, 1.11 2445 17 0.70 0.41, 1.11 5106 36 0.71 0.49, 0.97
Yes 73 0 0 0.00, 4.93 113 2 1.77 0.22, 6.25 186 2 1.08 0.13, 3.83
Concomitant ASA
No 2568 17 0.66 0.39, 1.06 2306 17 0.74 0.43, 1.18 4874 34 0.70 0.48, 0.97
Yes 166 2 1.20 0.15, 4.28 252 2 0.79 0.10, 2.84 418 4 0.96 0.26, 2.43
Chronic use of NSAIDs
No 2319 17 0.73 0.43, 1.17 2164 17 0.79 0.46, 1.25 4483 34 0.76 0.53, 1. 06
Yes 415 2 0.48 0.06, 1.73 394 2 0.51 0.06, 1.82 809 4 0.49 0.13, 1.26
N: number of patients; n: number of patients with major bleeding events (MBE)
ASA acetylsalicylic acid, CAD coronary artery disease, CHF chronic heart failure, CI confidence interval, NSAIDs non-steroidal anti-inflammatory drugs, THR total hip
replacement, TKR total knee replacement, VTE venous thromboembolism
Fig. 2 Effect of protocol-defined risk factors on the incidence of MBEs – odds ratios (95 % CI). Odds ratios, based on univariable logistic regression, were
calculated for presence versus absence of risk factor; CIs and p values are based on likelihood-ratio statistics. ASA acetylsalicylic acid, CAD coronary artery
disease, CHF chronic heart failure, CI confidence interval, MBE major bleeding event, NSAIDs non-steroidal anti-inflammatory drugs, VTE venous
thromboembolism
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Fig. 3 Cumulative incidence of MBEs over time from the start
of treatment, treated set. No events occurred after day 29 in
THR patients or day 14 in TKR patients. MBE major bleeding
event, THR total hip replacement, TKR total knee replacement
Table 3 Occurrence of primary efficacy endpoint overall and by pro
THR TKR
Risk factor subgroups N n Incidence % 95 % CI N n
All treated 2734 15 0.55 0.31, 0.90 2558 4
Active smoker
No 2269 13 0.57 0.31, 0.98 2319 3
Yes 465 2 0.43 0.05, 1.54 239 5
CAD
No 2602 13 0.50 0.27, 0.85 2371 3
Yes 132 2 1.52 0.18, 5.37 187 2
CHF
No 2680 15 0.56 0.31, 0.92 2485 4
Yes 54 0 0 0.00, 6.60 73 0
History of VTE
No 2661 15 0.56 0.32, 0.93 2445 3
Yes 73 0 0 0.00, 4.93 113 9
Concomitant ASA
No 2568 12 0.47 0.24, 0.81 2306 3
Yes 166 3 1.81 0.37, 5.19 252 1
Chronic use of NSAIDs
No 2319 13 0.56 0.30, 0.96 2164 3
Yes 415 2 0.48 0.06, 1.73 394 7
N number of patients, n number of patients with symptomatic VTE or who died of
ASA acetylsalicylic acid, CAD coronary heart disease, CHF chronic heart failure, CI co
replacement, TKR total knee replacement, VTE venous thromboembolism
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risk factor for recurrent VTE), there was no relevant dif-
ference in the incidence in patients with or without the
protocol-defined risk factors (Table 3 and Fig. 4). Pa-
tients with a history of VTE had a higher incidence of
the primary endpoint (4.84 %) than patients with no his-
tory of VTE (0.90 %); odds ratio for the composite end-
point for patients with versus those without a history of
VTE was 5.59 (95 % CI 2.53, 11.08; p = 0.0001). The latter
was driven by events in the TKR patients with a history of
VTE (Table 3). Sensitivity analyses, including multiple co-
variates in the logistic regression model, consistently sup-
ported results from the univariate logistic regression.
The incidence of the composite efficacy endpoint was
lower for THR patients (0.55 %) than for patients undergo-
ing knee surgery (1.56 %) (Table 3). The most frequent con-
tributor to the primary efficacy endpoint was symptomatic
distal DVT (39 events: 7/15 THR patients and 32/40 TKR
patients with an event had a symptomatic distal DVT).
In patients with sVTE or all-cause mortality (n = 55),
event onset occurred within the first 7 days of treatment
in 66.7 % (10/15) in the THR group and 70 % (28/40) in
the TKR group. Event onset occurred between 8 and
14 days after treatment initiation in 20 % (3/15) in the
THR group and 22.5 % (9/40) in the TKR group, andtocol-defined subgroup – treated set
Total
Incidence % 95 % CI N n Incidence % 95 % CI
0 1.56 1.12, 2.12 5292 55 1.04 0.78, 1.35
5 1.51 1.05, 2.09 4588 48 1.05 0.77, 1.38
2.09 0.68, 4.81 704 7 0.99 0.40, 2.04
8 1.60 1.14, 2.19 4973 51 1.03 0.76, 1.35
1.07 0.13, 3.81 319 4 1.25 0.34, 3.18
0 1.61 1.15, 2.19 5165 55 1.06 0.80, 1.38
0 0.00, 4.93 127 0 0 0.00, 2.86
1 1.27 0.86, 1.79 5106 46 0.90 0.66, 1.20
7.96 3.71, 14.58 186 9 4.84 2.24, 8.99
9 1.69 1.21, 2.30 4874 51 1.05 0.78, 1.37
0.40 0.01, 2.19 418 4 0.96 0.26, 2.43
3 1.52 1.05, 2.13 4483 46 1.03 0.75, 1.37
1.78 0.72, 3.63 809 9 1.11 0.51, 2.10
any cause
nfidence interval, NSAIDs non-steroidal anti-inflammatory drugs, THR total hip
Fig. 4 Effect of pre-specified risk factors on the incidence of sVTE and all-cause mortality, treated set. No events occurred in patients with CHF.
Odds ratios, based on univariable logistic regression, were calculated for presence versus absence of risk factor; CIs and p values are based on
likelihood-ratio statistics. ASA acetylsalicylic acid, CAD coronary artery disease, CHF chronic heart failure, CI confidence interval, NSAIDs
non-steroidal anti-inflammatory drugs, sVTE symptomatic venous thromboembolism
Rosencher et al. Thrombosis Journal  (2016) 14:8 Page 7 of 10>14 days after treatment initiation in 13.3 % (2/15) in
the THR group and 7.5 % (3/40) in the TKR group. Fig-
ure 5 shows the cumulative incidence of sVTE or all-
cause mortality over time.
Adverse events
Overall, treatment-emergent AEs (including bleeding
and efficacy outcome events) were observed in 987
(18.7 %) of the 5292 patients. Nausea (2.6 %), vomitingFig. 5 Cumulative incidence of sVTE or all-cause mortality over time
from the start of treatment, treated set. No new events occurred after
day 33 in THR patients or day 27 in TKR patients. sVTE symptomatic
venous thromboembolism, THR total hip replacement, TKR total
knee replacement(1.7 %), pyrexia (1.3 %) and operative haemorrhage
(1.3 %) were the only AEs observed in >1 % of patients. Ad-
verse events were considered drug-related by the investiga-
tor in 5.5 % of patients; operative haemorrhage (1.2 %) was
the only drug-related AE reported in >0.5 % of patients.
Three patients died during the study. One death due
to PE was considered by the investigator to be related to
the study drug. The other two, reported only as ‘death’,
were not considered by the investigator to be drug-
related. Serious AEs were reported in 2.6 % of patients;
the most frequently reported (in 0.2 % each) were DVT,
PE, device dislocation and ineffective drug, as reported
by the investigators. AEs resulted in discontinuation of
the study drug in 4.9 % of patients; DVT (0.6 %) was the
only AE that resulted in discontinuation of >0.5 % of pa-
tients. No safety concerns regarding ACS events were
identified overall (either during treatment or in the post-
study period) (Additional file 1: Supplementary Table 2).
Discussion
Results from this observational study showed that there
is no increased risk of bleeding with dabigatran 220 mg
once daily in patients undergoing THR or TKR (irre-
spective of the presence or absence of protocol-defined
risk factors for bleeding) in a real-world clinical setting
compared with the phase 3 clinical trials [4, 6, 7]. A his-
tory of VTE, a known risk factor for subsequent VTE
[12], was the only protocol-defined characteristic associ-
ated with an increased primary efficacy event rate (sVTE
or death). A higher event rate in patients with this risk
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but not for those undergoing THR (0 %).
The American College of Chest Physicians (ACCP)
guidelines estimated that, from 0 to 35 days, the cumula-
tive post-operative rate of nonfatal sVTE in patients
undergoing major orthopaedic surgery is 4.3 % in the ab-
sence of prophylaxis and 1.8 % with an LMWH [1]. The
incidence of the primary endpoint in this study, which
included fatal as well as nonfatal VTE events, was
1.04 % and therefore lower than the ACCP estimates
when patients were treated with an LMWH. Although
several factors may have influenced the incidence of
sVTE events and bleeding events, it is worth noting that
characteristics of the patients included in this observa-
tional study are broadly aligned with previously pub-
lished real-world data sets [13–15].
The primary efficacy endpoint is not directly compar-
able between this observational study and the phase 3
trials. In the observational study the primary endpoint was
sVTE and all-cause death during the treatment period and
the rate was primarily driven by the occurrence of symp-
tomatic distal DVTs. The primary endpoint in the phase 3
studies, RE-MODEL, RE-NOVATE and RE-NOVATE II,
was total VTE and all-cause mortality, and included
events observed during routine venography.
To explore the data more fully, we performed a post-
hoc analysis to facilitate closer comparison between this
observational study and the phase 3 results. To lessen
the differences introduced by the study designs, only pa-
tients ≤75 years of age, from outside the United States
and Canada, treated with dabigatran 220 mg once daily
with documented information on medication start date
and CrCl >50 mL/min, were included. Based on medical
judgement, the patient populations were similar in the
observational study and the phase 3 TKR and THR trials
of dabigatran, apart from a lower incidence of CAD at
baseline and a lower concomitant use of NSAIDs in the
observational, real-world setting study. Analysis in these
comparable populations (4999 patients from the obser-
vational study and 2118 from the phase 3 trials) showed
that safety and efficacy of dabigatran in this observa-
tional study were as favourable as those obtained in the
phase 3 dabigatran clinical trials. There was a similar or
lower risk of an MBE in this observational study com-
pared with the phase 3 trials in this post-hoc compari-
son: 0.62 % (95 % CI 0.36, 1.01) for THR and 0.74 %
(95 % CI 0.44, 1.17) for TKR in the observational study
compared with 0.65 % (95 % CI 0.24, 1.41) in RE-
NOVATE and 0.57 % (95 % CI 0.16, 1.46) in RE-
NOVATE II for THR, and 1.20 % (95 % CI 0.44, 2.58) in
RE-MODEL for TKR. In the same analysis, the incidence
of the composite of sVTE and all-cause mortality in the
observational study was 0.50 % (95 % CI 0.27, 0.86) for
THR and 1.40 % (95 % CI 0.97, 1.96) for TKR. This wasintermediate between the results from RE-NOVATE
(1.20 % [95 % CI 0.60, 2.13]) and RE-NOVATE II (0.14 %
[95 % CI 0.00, 0.08]) for THR, and higher than the results
from RE-MODEL (0.20 % [95 % CI 0.01, 1.10]) for TKR.
Differences in data collection methods (especially central
adjudication of events vs local investigator assessment),
patient populations and definitions of efficacy outcome
events in the observational study and the phase 3 trials
should be considered when interpreting the results from
this post-hoc analysis.
Contrary to the protocol recommendation and to
ACCP recommendations, a subset of sites performed
routine ultrasound examinations to detect VTE; asymp-
tomatic as well as sVTE events could therefore have
been reported. We noticed in a stratified analysis by
country that the incidence of sVTE and all-cause mortal-
ity was higher in France (2.15 %), where duplex sonog-
raphy is routine clinical practice in some institutions
[16], than in other countries (0–1.37 %). Within France,
the incidence was highest for patients undergoing knee
surgery (4.38 % vs 0.67 % for hip surgery patients). A
further post-hoc analysis showed that the incidence of
sVTE and all-cause mortality was lower when patients
from sites that routinely performed ultrasound examina-
tions were excluded (n = 405); the incidence of sVTE
and all-cause mortality decreased to 0.86 % (95 % CI
0.62, 1.16) in the remaining 4887 patients (1.12 % in
TKR patients [95 % CI 0.74, 1.63]; and 0.60 % in THR
patients [95 % CI 0.34, 1.00]). There was a significant ef-
fect of diagnosis using routine ultrasound on the reported
incidence of sVTE and all-cause mortality (odds ratio 3.83
for sites using vs not using routine ultrasound [95 % CI
1.96, 6.99; p = 0.0002]). This difference was driven by a
lower incidence of patients with distal symptomatic DVT.
Diagnosis using routine ultrasound may therefore explain
the higher event rates in TKR patients compared with the
rate obtained in phase 3 clinical trials.
It is unclear whether the low incidence of symptomatic
VTE and all-cause mortality in THR patients with a his-
tory of VTE (0 % compared with 0.56 % in those without
a history of VTE) has a medical explanation. It may be a
‘chance’ finding due to sample size. Only 73 patients
with a history of VTE underwent hip surgery, so even if
the risk increase (due to history of VTE) were as high as
that observed for the knee surgery group, we would only
expect two to three patients with an event in the THR
patients with history of VTE. The use of duplex sonog-
raphy of the calf in some study centres may also have
contributed to the relatively greater difference in the in-
cidence of the primary efficacy outcome between the
TKR patients with and without a history of VTE (7.96 %
vs 1.27 %). Asymptomatic VTE could be interpreted as
symptomatic VTE in knee surgery because of calf
haematoma and oedema, but in hip surgery, there is no
Rosencher et al. Thrombosis Journal  (2016) 14:8 Page 9 of 10calf haematoma and thus no possibility to attribute an
asymptomatic DVT to a symptomatic event.
Further potential limitations of this observational
study include a lack of control group, diagnosis based
only on the investigator’s clinical judgement (which
could have resulted in false positive or negative findings)
and a possible bias in the selection of patients. The ex-
pected sample size ≥400 patients was not reached in all
subgroups, therefore, the power to detect significant dif-
ferences in rates on a descriptive basis was decreased,
particularly for the CAD and CHF groups. However, the
point estimates did not indicate any relevant increase in
risk in these groups. A formal comparison of outcomes be-
tween THR and TKR surgery groups was not considered
worthwhile because of significant differences in patient
characteristics and the expectation of different outcomes
based on the body of previously published findings.
It is important to note that the favourable AE profile in
this observational study was comparable with that obtained
in the dabigatran phase 3 trials. No increased ACS signal
was detected with dabigatran compared with enoxaparin
during or after treatment in a pooled analysis of pivotal
phase 3 dabigatran trials [9]. Results from this observa-
tional study confirm the low incidence of ACS during dabi-
gatran treatment in a real-world orthopaedic setting.
Conclusion
The risk factors that were evaluated in the protocol-
defined subgroups had little impact on the incidence of
major bleeding in patients undergoing TKR or THR in a
routine clinical setting. With the exception of a history of
VTE, the protocol-defined risk factors for bleeding did
not have an impact on the incidence of sVTE and overall
mortality. Results from this real-world observational study
are reassuring and supportive of the safety and efficacy re-
sults obtained in dabigatran phase 3 clinical trials.
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